Efficacy and safety of a pepsin egg white hydrolysate on metabolic syndrome: A first-in-human, proof-of-concept pilot study
Journal of Functional Foods · 2026-11 · 146 · 107518
DOI: 10.1016/j.jff.2026.107518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Functional Foods, 2026-11. Verfasst von Marta Garcés-Rimón und 5 weiteren Autor:innen. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España.
Abstract (Originalsprache)
Metabolic syndrome (MetS) is a major public health challenge requiring novel multi-target therapeutic approaches. The aim of this preliminary pilot study was to establish a proof-of-concept regarding the safety, feasibility, and therapeutic potential of dietary supplementation with a specific Egg White Hydrolysate (EWH) on individuals diagnosed with MetS. Eleven adults completed the 14-week protocol (4 g/day EWH). EWH was well tolerated, with high compliance and no adverse events. Intra-individual trajectory analysis revealed unique, baseline-dependent efficacy: participants with baseline hyperglycemia, hyperinsulinemia, hyperlipidemia, or systolic hypertension tended toward physiological normalization; two participants completely reversed their diagnostic MetS status. Microbiological analysis demonstrated significant gut microbiota modulation, increasing beneficial Bifidobacterium and Akkermansia , while reducing pathobiont Enterobacteriaceae . Ultimately, this study successfully establishes the clinical safety and target engagement of EWH, delivering the essential preliminary translational foundation required for future large-scale trials.
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España
Zitieren
APA
Garcés-Rimón, M., Requena, T., García, A., Puerro, M., Martínez-Cuesta, M. C., & Miguel, M. (2026). Efficacy and safety of a pepsin egg white hydrolysate on metabolic syndrome: A first-in-human, proof-of-concept pilot study. Journal of Functional Foods, 146, 107518. https://doi.org/10.1016/j.jff.2026.107518
Vancouver
Garcés-Rimón M, Requena T, García A, Puerro M, Martínez-Cuesta MC, Miguel M. Efficacy and safety of a pepsin egg white hydrolysate on metabolic syndrome: A first-in-human, proof-of-concept pilot study. Journal of Functional Foods. 2026;146:107518. doi:10.1016/j.jff.2026.107518
BibTeX
@article{GarcsRimn2026,
author = {Garcés-Rimón, Marta and Requena, Teresa and García, Amelia and Puerro, Miguel and Martínez-Cuesta, M. Carmen and Miguel, Marta},
title = {Efficacy and safety of a pepsin egg white hydrolysate on metabolic syndrome: A first-in-human, proof-of-concept pilot study},
journal = {Journal of Functional Foods},
year = {2026},
volume = {146},
pages = {107518},
doi = {10.1016/j.jff.2026.107518}
}
EUVIMED